If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?

Haass, Christian und Selkoe, Dennis (2022): If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?
In: PLOS Biology 20(7), e3001694

Abstract

Strong genetic evidence supports an imbalance between production and clearance of amyloid beta-protein (A beta) in people with Alzheimer disease (AD). Microglia that are potentially involved in alternative mechanisms are actually integral to the amyloid cascade. Fluid biomarkers and brain imaging place accumulation of A beta at the beginning of molecular and clinical changes in the disease. So why have clinical trials of anti-amyloid therapies not provided clear-cut benefits to patients with AD? Can anti-amyloid therapies robustly decrease A beta in the human brain, and if so, could this lowering be too little, too late? These central questions in research on AD are being urgently addressed.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin ; Medizin > Munich Cluster for Systems Neurology (SyNergy)
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1544-9173
• Sprache: Englisch
• DFG: Gefördert durch die Deutsche Forschungsgemeinschaft (DFG) - 390857198